241 related articles for article (PubMed ID: 28007630)
1. Improving the Accuracy of Mesothelioma Diagnosis in China.
Guo Z; Carbone M; Zhang X; Su D; Sun W; Lou J; Gao Z; Shao D; Chen J; Zhang G; Hu J; Chen K; Wang F; Pass HI; Yu H; Napolitano A; Yang H; Mao W
J Thorac Oncol; 2017 Apr; 12(4):714-723. PubMed ID: 28007630
[TBL] [Abstract][Full Text] [Related]
2. Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma.
Carbone M; Shimizu D; Napolitano A; Tanji M; Pass HI; Yang H; Pastorino S
Oncotarget; 2016 Sep; 7(37):59314-59321. PubMed ID: 27447750
[TBL] [Abstract][Full Text] [Related]
3. Utility and pitfalls of immunohistochemistry in the differential diagnosis between epithelioid mesothelioma and poorly differentiated lung squamous cell carcinoma.
Kushitani K; Amatya VJ; Okada Y; Katayama Y; Mawas AS; Miyata Y; Okada M; Inai K; Kishimoto T; Takeshima Y
Histopathology; 2017 Feb; 70(3):375-384. PubMed ID: 27589012
[TBL] [Abstract][Full Text] [Related]
4. [Comparing the results of pathologic diagnosis of mesothelioma between Chinese and Japanese experts].
Lou J; Gao Z; Jiang Z; Chen J; Chen R; Zhang X
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2015 Jan; 33(1):33-6. PubMed ID: 25876971
[TBL] [Abstract][Full Text] [Related]
5. Asbestos textile production linked to malignant peritoneal and pleural mesothelioma in women: Analysis of 28 cases in Southeast China.
Gao Z; Hiroshima K; Wu X; Zhang J; Shao D; Shao H; Yang H; Yusa T; Kiyokawa T; Kobayashi M; Shinohara Y; Røe OD; Zhang X; Morinaga K
Am J Ind Med; 2015 Oct; 58(10):1040-9. PubMed ID: 26147229
[TBL] [Abstract][Full Text] [Related]
6. [Clinical and pathological profile of the pleural malignant mesothelioma: A retrospective study about 30 cases].
Mlika M; Lamzirbi O; Limam M; Mejri N; Ben Saad S; Chaouch N; Ben Miled K; Marghli A; Mezni F
Rev Pneumol Clin; 2018 Dec; 74(6):427-435. PubMed ID: 30293912
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of prognostic histological parameters proposed for pleural mesothelioma in diffuse malignant peritoneal mesothelioma. A short report.
Pezzuto F; Vimercati L; Fortarezza F; Marzullo A; Pennella A; Cavone D; Punzi A; Caporusso C; d'Amati A; Lettini T; Serio G
Diagn Pathol; 2021 Jul; 16(1):64. PubMed ID: 34294087
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemistry in Peritoneal Mesothelioma: A Single-Center Experience of 244 Cases.
Tandon RT; Jimenez-Cortez Y; Taub R; Borczuk AC
Arch Pathol Lab Med; 2018 Feb; 142(2):236-242. PubMed ID: 29048219
[TBL] [Abstract][Full Text] [Related]
9. BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests.
Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Iwasaki A; Okamoto T; Oda Y; Honda H; Nabeshima K
Pathol Int; 2016 Oct; 66(10):563-570. PubMed ID: 27614970
[TBL] [Abstract][Full Text] [Related]
10. Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses.
Kawai T; Tominaga S; Hiroi S; Ogata S; Nakanishi K; Kawahara K; Sonobe H; Hiroshima K
J Clin Pathol; 2016 Aug; 69(8):706-12. PubMed ID: 26729015
[TBL] [Abstract][Full Text] [Related]
11. Differential Diagnosis of Epithelioid Malignant Mesothelioma With Lung and Breast Pleural Metastasis: A Systematic Review Compared With a Standardized Panel of Antibodies-A New Proposal That May Influence Pathologic Practice.
Le Stang N; Burke L; Blaizot G; Gibbs AR; Lebailly P; Clin B; Girard N; Galateau-Sallé F;
Arch Pathol Lab Med; 2020 Apr; 144(4):446-456. PubMed ID: 31389715
[TBL] [Abstract][Full Text] [Related]
12. [Loss of BRCA associated protein 1 expression in malignant mesothelioma and its diagnostic application].
Guo ZY; Sun WY; Michele Y; Zhang JL; Hu D; Su HN; Yang WM; Mao W
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):699-703. PubMed ID: 29050072
[No Abstract] [Full Text] [Related]
13. Calretinin-expressing lung adenocarcinoma: Distinct characteristics of advanced stages, smoker-type features, and rare expression of other mesothelial markers are useful to differentiate epithelioid mesothelioma.
Matsuda M; Ninomiya H; Wakejima R; Inamura K; Okumura S; Mun M; Kitagawa M; Ishikawa Y
Pathol Res Pract; 2020 Mar; 216(3):152817. PubMed ID: 32008868
[TBL] [Abstract][Full Text] [Related]
14. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
[TBL] [Abstract][Full Text] [Related]
15. Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
Yoshimura M; Kinoshita Y; Hamasaki M; Matsumoto S; Hida T; Oda Y; Iwasaki A; Nabeshima K
Lung Cancer; 2019 Apr; 130():187-193. PubMed ID: 30885343
[TBL] [Abstract][Full Text] [Related]
16. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.
Carbone M; Adusumilli PS; Alexander HR; Baas P; Bardelli F; Bononi A; Bueno R; Felley-Bosco E; Galateau-Salle F; Jablons D; Mansfield AS; Minaai M; de Perrot M; Pesavento P; Rusch V; Severson DT; Taioli E; Tsao A; Woodard G; Yang H; Zauderer MG; Pass HI
CA Cancer J Clin; 2019 Sep; 69(5):402-429. PubMed ID: 31283845
[TBL] [Abstract][Full Text] [Related]
17. Mesothelioma: current perspectives.
Taylor RA; Johnson LP
West J Med; 1981 May; 134(5):379-83. PubMed ID: 7257347
[TBL] [Abstract][Full Text] [Related]
18. Distinction between pleural mesothelioma and pulmonary adenocarcinoma using MOC31 in an asbestos sprayer.
Ryan PJ; Oates JL; Crocker J; Stableforth DE
Respir Med; 1997 Jan; 91(1):57-60. PubMed ID: 9091974
[TBL] [Abstract][Full Text] [Related]
19. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
20. [Research progress on immunohistochemical diagnostic markers for malignant pleural mesothelioma].
Pu YQ; Zhang YP; Xiong W
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2023 Nov; 41(11):869-875. PubMed ID: 38073220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
